Karim MM, Butt AS. Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment. World J Gastroenterol 2024; 30(17): 2371-2373 [PMID: 38813051 DOI: 10.3748/wjg.v30.i17.2371]
Corresponding Author of This Article
Amna Subhan Butt, FCPS, MBBS, MSc, Associate Professor, Department of Medicine, Aga Khan University Hospital, Stadium Road, Karachi 74800, Pakistan. amna.subhan@aku.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 7, 2024; 30(17): 2371-2373 Published online May 7, 2024. doi: 10.3748/wjg.v30.i17.2371
Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment
Masood Muhammad Karim, Amna Subhan Butt
Masood Muhammad Karim, Department of Gastroenterology, The Aga Khan University Hospital, Karachi 74800, Sindh, Pakistan
Amna Subhan Butt, Department of Medicine, Aga Khan University Hospital, Karachi 74800, Pakistan
Author contributions: Karim MM and Butt AS designed research and performed research (literature review); Karim MM wrote the letter; Butt AS revised the letter.
Conflict-of-interest statement: Both authors have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amna Subhan Butt, FCPS, MBBS, MSc, Associate Professor, Department of Medicine, Aga Khan University Hospital, Stadium Road, Karachi 74800, Pakistan. amna.subhan@aku.edu
Received: January 30, 2024 Revised: March 12, 2024 Accepted: April 18, 2024 Published online: May 7, 2024 Processing time: 95 Days and 14 Hours
Abstract
The diagnosis of non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease only on the basis of laboratory parameter score such as Hepatic Steatosis Index which includes liver enzymes, gender, basal metabolic index, and presence of diabetic mellitus is not sufficient to exclude other causes of deranged liver enzymes especially medications and autoimmune related liver diseases. As the guideline suggests ultrasound is the preferred first-line diagnostic procedure for imaging of NAFLD, as it provides additional diagnostic information and the combination of biomarkers/scores and transient elastography might confer additional diagnostic accuracy and evident from previous similar studies too.
Core Tip: Combining imaging modalities along with laboratory parameter-based scores increases the diagnostic yield of non-alcoholic fatty liver disease, and helps in the exclusion of the other secondary causes.
